Balancing the risk and rewards of utilizing organs from hepatitis C viremic donorsSise, Meghan E.a; Strohbehn, Ian A.b; Bethea, Emilyb; Gustafson, Jenna L.b; Chung, Raymond T.bCurrent Opinion in Organ Transplantation: June 2019 - Volume 24 - Issue 3 - p 351–357 doi: 10.1097/MOT.0000000000000651 ETHICAL CONSIDERATIONS OF ALLOCATION: Edited by David A. Axelrod Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation. Recent findings Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of infection after transplantation. Summary In this manuscript, we review the risks and rewards of utilizing hepatitis C viremic organs for transplantation. aDepartment of Medicine, Division of Nephrology bDepartment of Medicine, Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts, USA Correspondence to Raymond T. Chung, Gastrointestinal Unit, Massachusetts General Hospital, 55 Fruit Street, Blake 4, Boston, MA 02114, USA. E-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.